The Multinational Medical Business Is Overweight "China Intelligent Manufacturing": Varian Will Increase Its Investment In China 3 Times Next Year.

"We hope to introduce continuously advanced cancer treatment technologies to cancer patients in China, and plan to increase investment in fixed assets by three times in 2020, expanding production lines and Varian R & D centers." At the second annual fair, Wei Sitao, President and chief executive of Varian Medical System, said in an interview with the twenty-first Century economic news reporter.

At the Expo, Varian Asia Pacific's first artificial intelligence driven adaptive radiotherapy technology, the new EthosTM smart radiotherapy platform, the only proton therapy system of the Expo, ProBeam, AI and 5G intelligent medical conjoint solutions and other advanced equipment and techniques have all appeared.

In fact, many multinational companies, including Varian, exhibited the most advanced technology, heavy products and so on at this fair. In response, Huo Jianguo, the president of the international trade and Economic Cooperation Research Institute of the former Ministry of Commerce and vice president of the China World Trade Organization Research Association, pointed out to the twenty-first Century economic report reporter that the "spillover effect" of the fair has become an important platform for service trade. At the same time, we can see that the trend of world economic integration is becoming stronger and stronger.

Huge market in China

"We hope to build a more comprehensive cancer treatment ecosystem in China and introduce more advanced technology and treatment solutions in China," he said. Wei Sitao pointed out to the twenty-first Century economic news reporter.

This Varian has a number of sophisticated equipment and technology debut at the Expo. For example, the Ethos intelligent radiotherapy platform, the first in Asia Pacific region, has pioneered the realization of multi-modal online adaptive therapy in the world. Under artificial intelligence driving, it has the ability to automatically integrate MR, CT and PET multimodality images. It can accurately capture the dynamic changes of tumor (including location, size, shape, etc.), and shorten the adaptive treatment time to 15 minutes. Each radiotherapy will prescribe precise and personalized "4D prescription" to minimize unnecessary side effects.

At this session, Varian exhibited its leading proton therapy system, tumor radiotherapy peak technology ProBeam proton therapy system. The proton platform can also implement advanced technology Flash (flash) particle therapy technology, which represents the future of radiotherapy. Flash particle therapy uses ultra high dose rate ultra high speed external beam therapy, which greatly improves the current clinical proton therapy intensity.

Compared with the first round of the Expo, Varian put more money into it, Wei Sitao told the twenty-first Century economic analysis reporter. Because China has huge market and demand, there are also many talented people in China who can jointly research and develop, and from the production point of view, China can also guarantee high quality and competitive production.

Data show that since 2015, China has increased about 3900000 cancer patients annually, and the number of cancer patients has reached 2 million 330 thousand. WHO recommends that 50% of cancer patients need radiation therapy. Another indicator is that there are 3 to 4 medical linear accelerators per million people in a country, while China now has less than 2 people per million, less than the United States, France, the United Kingdom and so on.

"At present, the demand for radiation therapy in Chinese grass-roots hospitals is increasing. The government also encourages the development of primary health care and serious illness." with the construction of urban cancer centers, more and more patients' needs will be met, which will also improve the level of cancer treatment in China. Wei Sitao pointed out.

Varian, vice president of global health and President of Greater China, told the twenty-first Century economic report that Varian is building an ecological environment to promote the development of cancer therapy in China, including the latest treatment methods, including early diagnosis, gene radiotherapy, individualization, submolecular typing, radiosurgery, adaptation, clinical cancer management and survival, including radiotherapy combined with other therapies such as immunotherapy.

Increase investment in China

At the exhibition venue, Varian's technology, heavy products and frontiers in cancer fighting have become the focus of attention. Many delegations from Beijing, Tianjin, Guangdong, Zhejiang, Sichuan, Shandong, Qinghai, Yunnan and other provinces signed a series of strategic cooperation agreements with Varian Medical, in order to continuously promote and strengthen the rapid development of regional radiotherapy. Shanghai Shen Kang Hospital Development Center has again signed a procurement agreement with Varian Medical Aid to help develop the Shanghai tumor radiotherapy in Ruijin Affiliated Hospital of Shanghai Jiaotong University School of Medicine.

"With China's policy of decentralization and better business environment, Varian is more confident of its investment, development and development in China. China has become the largest market in Varian except the United States. China's business grows at a rate of two digits per year, resulting from the promotion of China's business environment and confidence in China's medical development prospects. Varian has declared its participation in the third annual fair, and the exhibition area will continue to expand. Zhang Xiao pointed out.

Huo Jian Guo pointed out to the twenty-first Century economic news reporter that the Chinese government is constantly improving its business environment, and is also doing a good job in supporting the business environment, including market legalization, openness and transparency, and ensuring the stability of law enforcement. This will attract more investment into the Chinese market.

In fact, as the first batch of high-end medical enterprises to enter China after the reform and opening up, as early as 2007, Varian Medical treatment established the only medical linear accelerator research and development base in North America's Beijing Yizhuang economic development zone. It is the first enterprise in the industry to set up production and scientific research bases in China.

"We will continuously increase the Chinese market and plan to increase investment in fixed assets by three times in 2020, expanding production lines and Varian R & D centers. At that time, Varian China will become the most complete product line R & D and production base in Varian. Wei Sitao said.

It is understood that as at the end of June 2019, the output value of Varian factory increased by 73% compared with the same period in 2018, while the export volume in the first half of 2019 increased by 70% compared with the same period in 2018. It is estimated that by the end of 2020, the capacity will increase by 50% compared with that in September 2019. At that time, Varian will introduce the world's most advanced radiotherapy product line to the high-end linear accelerator. Then China will become the R & D and production base of vari safety ball's most complete product line.

"Many products are developed and manufactured in China, but they also serve the global market, and the development of Varian has also complied with the trend of global economic integration." Wei Sitao told reporters on twenty-first Century economic report.

In addition to Wali an, many multinationals are overweight Chinese investment, while "made in China" is also serving the global market.

For instance, at this Expo, AstraZeneca and CICC announced that they would jointly set up the global medical and health industry fund to raise 1 billion US dollars. We should take advantage of both sides to build a special fund focusing on the medical and health industry, accelerate the optimization and integration of China's medical resources, expand overseas innovation introduction and local innovation incubation.

During the "Lilai Suzhou factory tour" organized by Lilly during the Expo, Li Lai Wen, President and general manager of Lilly China, told the twenty-first Century economic correspondent: "our high-tech technology is applied to China's production plants, such as the Suzhou insulin production line to be put into operation, not only for the production of insulin in China, but also for the production of high quality insulin throughout the world. In addition, we have many local partners, such as XinDa biology, Hutchison Whampoa medicine, etc., in the future, we will carry out some global R & D and production so that we can "root China, benefit China and benefit the whole world".